Summit Therapeutics Inc. (SMMT)
NASDAQ • Healthcare
Last close at October 2, 2026 at 20:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 19
in 15 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Summit Therapeutics’ loss per share trailed expectations in the second fiscal quarter of 2026, based on preliminary results reported July 23, 2026, with EPS of -$0.28 trailing the -$0.27 estimate by -$0.01. The quarter’s results reflected the company’s clinical-stage focus, with its pipeline centered on anti-infective development including the ridinilazole program for Clostridioides difficile infection. On a GAAP basis, operating income was a loss of roughly $220.5 million, while net income was a loss of about $215.7 million, up ~48% from a loss of roughly $412.2 million a year ago. Cash flow from operations was negative at about $167.8 million. For the next period, consensus calls for EPS of -$0.28 on revenue of $71,429.00.
Next report — what to expect
Summit Therapeutics Inc. (SMMT) is scheduled to report earnings on October 19, 2026. Wall Street is looking for consensus EPS of -$0.28 on revenue of $71,429.00. In recent history, the company has beaten EPS in 3 of its 8 most recent quarters, making the upcoming print a fresh check on execution versus expectations.
About Summit Therapeutics Inc.
Summit Therapeutics Inc. is a NASDAQ-listed biotechnology company focused on discovering, developing, and commercializing therapeutic solutions. In qualitative terms, it is a clinical-stage healthcare business built around anti-infective drug development, with a pipeline centered chiefly on Clostridioides difficile infection, or CDI, including the Phase III program ridinilazole.
Today's Snapshot
SMMT closed slightly higher at 16.75, in line with a flat sector. Trading was lighter than usual, with volume about two-thirds of its usual level. Summit Therapeutics agreed with AstraZeneca, a drugmaker, to test cancer-drug combinations in clinical trials.
Trading Volume
Below 10d avg (8.3M)
5M
vs S&P 500 Today
Moderate Underperformance
-0.39%
Updated: October 2, 2026 at 20:03 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$15.75 - $16.59Buy
- RSI (14)54.50Neutral
- Stochastic %K (14, 3, 3)41.09Neutral
- MACD Level (12, 26)0.35Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.